![Peter Smith](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 10 253 $ al 31/10/2026
Peter M.
Smith was the founder of Onyvax Ltd., founded in 1996, where the title held was Finance Director from 1996 to 2013.
Dr. Smith is the founder of Amala Therapeutics Pty Ltd., founded in 2015, holding the title of Chief Executive Officer since 2015.
Current jobs include Chief Executive Officer & Director at Myrio Therapeutics Pty Ltd. since 2016, Executive Chairman at Racura Oncology Ltd. since 2024, and Non-Executive Director at MycRX since 2018.
Former jobs include Chief Executive Officer & Managing Director at CSL Innovation Pty Ltd. from 2003 to 2005, Chief Executive Officer, Executive Director & MD at The Sustainable Nutrition Group Pty Ltd. from 2012 to 2013, President, Chief Executive Officer & Director at Audeo Oncology, Inc. from 2012 to 2013, Chairman & Chief Executive Officer at Cerylid Biosciences Ltd. from 2005 to 2006, and Non-Executive Chairman at Ascend Biopharmaceuticals Ltd. Education includes undergraduate and doctorate degrees from the University of Cambridge.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 26/11/2025 | 9.433 ( 0 % ) | 10 253 $ | 31/10/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| RACURA ONCOLOGY LTD | Presidente | 01/09/2024 |
Myrio Therapeutics Pty Ltd.
 Myrio Therapeutics Pty Ltd. BiotechnologyHealth Technology Develops therapeutic antibodies targeting intracellular proteins through their proprietary Retained Display (ReD) platform | Director Ejecutivo | 01/11/2016 |
MycRx
 MycRx Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that develops small molecule inhibitors of the Myc oncoprotein | Director/Miembro de la Junta | 01/02/2018 |
| Empresas | Cargo | Fin |
|---|---|---|
| THE SUSTAINABLE NUTRITION GROUP LTD | Director Ejecutivo | 25/01/2013 |
Audeo Oncology, Inc.
 Audeo Oncology, Inc. Pharmaceuticals: MajorHealth Technology Provides cancer treatment services | Director Ejecutivo | 25/01/2013 |
Cerylid Biosciences Ltd.
 Cerylid Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Director Ejecutivo | 01/01/2006 |
| ZENYTH THERAPEUTICS LIMITED | Director Ejecutivo | - |
Ascend Biopharmaceuticals Ltd.
 Ascend Biopharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Develops cancer treatments | Presidente | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 10 |
|---|---|
CSL Innovation Pty Ltd.
 CSL Innovation Pty Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
The Sustainable Nutrition Group Pty Ltd.
 The Sustainable Nutrition Group Pty Ltd. Agricultural Commodities/MillingProcess Industries Produces, manufactures and sells hemp products | Process Industries |
Audeo Oncology, Inc.
Audeo Oncology, Inc. Pharmaceuticals: MajorHealth Technology Provides cancer treatment services | Health Technology |
University of Cambridge
 University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cerylid Biosciences Ltd.
Cerylid Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Onyvax Ltd.
 Onyvax Ltd. Miscellaneous Commercial ServicesCommercial Services Develops cancer remedy therapies | Commercial Services |
Ascend Biopharmaceuticals Ltd.
Ascend Biopharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Develops cancer treatments | Health Technology |
Race Oncology Ltd.
 Race Oncology Ltd. Pharmaceuticals: MajorHealth Technology Manufactures drugs for cancer | Health Technology |
MycRx
MycRx Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that develops small molecule inhibitors of the Myc oncoprotein | Commercial Services |
Myrio Therapeutics Pty Ltd.
Myrio Therapeutics Pty Ltd. BiotechnologyHealth Technology Develops therapeutic antibodies targeting intracellular proteins through their proprietary Retained Display (ReD) platform | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
